{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,17]],"date-time":"2026-01-17T20:44:13Z","timestamp":1768682653331,"version":"3.49.0"},"reference-count":28,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":1554,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Arthritis & Rheumatism"],"published-print":{"date-parts":[[2011,6]]},"DOI":"10.1002\/art.30310","type":"journal-article","created":{"date-parts":[[2011,2,26]],"date-time":"2011-02-26T16:00:43Z","timestamp":1298736043000},"page":"1479-1485","source":"Crossref","is-referenced-by-count":129,"title":["Tumor necrosis factor therapy and the risk of serious infection and malignancy in patients with early rheumatoid arthritis: A meta-analysis of randomized controlled trials"],"prefix":"10.1002","volume":"63","author":[{"given":"Andrew E.","family":"Thompson","sequence":"first","affiliation":[]},{"given":"Scott W.","family":"Rieder","sequence":"additional","affiliation":[]},{"given":"Janet E.","family":"Pope","sequence":"additional","affiliation":[]}],"member":"311","published-online":{"date-parts":[[2011,5,31]]},"reference":[{"key":"10.1002\/art.30310-BIB1|cit1","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1002\/art.23721","article-title":"American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis","volume":"59","author":"Saag","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1002\/art.30310-BIB2|cit2","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1097\/BOR.0b013e3282f4b392","article-title":"The safety of anti-tumour necrosis factor therapy in rheumatoid arthritis","volume":"20","author":"Askling","year":"2008","journal-title":"Curr Opin Rheumatol"},{"key":"10.1002\/art.30310-BIB3|cit3","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1001\/jama.295.19.2275","article-title":"Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials","volume":"295","author":"Bongartz","year":"2006","journal-title":"JAMA"},{"key":"10.1002\/art.30310-BIB4|cit4","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1136\/ard.2006.062760","article-title":"Time-dependent increase in risk of hospitalisation with infection among Swedish RA patients treated with TNF antagonists","volume":"66","author":"Askling","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"10.1002\/art.30310-BIB5|cit5","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1136\/ard.2008.094904","article-title":"Etanercept therapy in rheumatoid arthritis and the risk of malignancies: a systematic review and individual patient data meta-analysis of randomised controlled trials","volume":"68","author":"Bongartz","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1002\/art.30310-BIB6|cit6","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1159\/000055014","article-title":"Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement","volume":"23","author":"Moher","year":"2000","journal-title":"Onkologie"},{"key":"10.1002\/art.30310-BIB7|cit7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(95)00134-4","article-title":"Assessing the quality of reports of randomized clinical trials: is blinding necessary?","volume":"17","author":"Jadad","year":"1996","journal-title":"Control Clin Trials"},{"key":"10.1002\/art.30310-BIB8|cit8","doi-asserted-by":"crossref","first-page":"156","DOI":"10.2522\/ptj.20070147","article-title":"Scales to assess the quality of randomized controlled trials: a systematic review","volume":"88","author":"Olivo","year":"2008","journal-title":"Phys Ther"},{"key":"10.1002\/art.30310-BIB9|cit9","volume-title":"Review Manager (RevMan) software for preparing and maintaining Cochrane Reviews: version 5.0","year":"2009"},{"key":"10.1002\/art.30310-BIB10|cit10","doi-asserted-by":"crossref","first-page":"2272","DOI":"10.1002\/art.24638","article-title":"Golimumab, a human anti-tumor necrosis factor \u03b1 monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active rheumatoid arthritis: twenty-four-week results of a phase III, multicenter, randomized, double-blind, placebo-controlled study of golimumab before methotrexate as first-line therapy for early-onset rheumatoid arthritis","volume":"60","author":"Emery","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1002\/art.30310-BIB11|cit11","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/S0140-6736(04)15640-7","article-title":"Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial","volume":"363","author":"Klareskog","year":"2004","journal-title":"Lancet"},{"key":"10.1002\/art.30310-BIB12|cit12","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1136\/ard.2008.101659","article-title":"Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial","volume":"68","author":"Smolen","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1002\/art.30310-BIB13|cit13","doi-asserted-by":"crossref","first-page":"3319","DOI":"10.1002\/art.23964","article-title":"Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study","volume":"58","author":"Keystone","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1002\/art.30310-BIB14|cit14","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S0140-6736(08)61000-4","article-title":"Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial","volume":"372","author":"Emery","year":"2008","journal-title":"Lancet"},{"key":"10.1002\/art.30310-BIB15|cit15","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1002\/art.21519","article-title":"The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment","volume":"54","author":"Breedveld","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1002\/art.30310-BIB16|cit16","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1056\/NEJM200011303432201","article-title":"A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis","volume":"343","author":"Bathon","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1002\/art.30310-BIB17|cit17","doi-asserted-by":"crossref","first-page":"3432","DOI":"10.1002\/art.20568","article-title":"Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial","volume":"50","author":"St.Clair","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1002\/art.30310-BIB18|cit18","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1002\/art.24106","article-title":"Effect of the early use of the anti-tumor necrosis factor adalimumab on the prevention of job loss in patients with early rheumatoid arthritis","volume":"59","author":"Bejarano","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1002\/art.30310-BIB19|cit19","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S0140-6736(09)60944-2","article-title":"Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in patients with early rheumatoid arthritis (SWEFOT trial): 1-year results of a randomised trial","volume":"374","author":"Van Vollenhoven","year":"2009","journal-title":"Lancet"},{"key":"10.1002\/art.30310-BIB20|cit20","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.1001\/jama.296.18.2201-b","article-title":"Risk of serious infections and malignancies with anti-TNF antibody therapy in rheumatoid arthritis","volume":"296","author":"Okada","year":"2006","journal-title":"JAMA"},{"key":"10.1002\/art.30310-BIB21|cit21","doi-asserted-by":"crossref","first-page":"2757","DOI":"10.1002\/art.22056","article-title":"Tumor necrosis factor \u03b1 antagonist use and cancer in patients with rheumatoid arthritis","volume":"54","author":"Setoguchi","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1002\/art.30310-BIB22|cit22","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1002\/art.20311","article-title":"Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients","volume":"50","author":"Wolfe","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1002\/art.30310-BIB23|cit23","doi-asserted-by":"crossref","first-page":"2886","DOI":"10.1002\/art.22864","article-title":"Biologic treatment of rheumatoid arthritis and the risk of malignancy: analyses from a large US observational study","volume":"56","author":"Wolfe","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1002\/art.30310-BIB24|cit24","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1136\/ard.2004.033241","article-title":"Haematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists","volume":"64","author":"Askling","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"10.1002\/art.30310-BIB25|cit25","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1136\/ard.2004.033993","article-title":"Risks of solid cancers in patients with rheumatoid arthritis and after treatment with tumour necrosis factor antagonists","volume":"64","author":"Askling","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"10.1002\/art.30310-BIB26|cit26","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1002\/art.20217","article-title":"Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial","volume":"50","author":"Keystone","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1002\/art.30310-BIB27|cit27","doi-asserted-by":"crossref","first-page":"478","DOI":"10.7326\/0003-4819-130-6-199903160-00004","article-title":"Etanercept therapy in rheumatoid arthritis: a randomized, controlled trial","volume":"130","author":"Moreland","year":"1999","journal-title":"Ann Intern Med"},{"key":"10.1002\/art.30310-BIB28|cit28","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1056\/NEJM200011303432202","article-title":"Infliximab and methotrexate in the treatment of rheumatoid arthritis","volume":"343","author":"Lipsky","year":"2000","journal-title":"N Engl J Med"}],"container-title":["Arthritis & Rheumatism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fart.30310","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1002\/art.30310\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,30]],"date-time":"2021-06-30T21:33:28Z","timestamp":1625088808000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/art.30310"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,5,31]]},"references-count":28,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2011,6]]}},"URL":"https:\/\/doi.org\/10.1002\/art.30310","relation":{},"ISSN":["0004-3591"],"issn-type":[{"value":"0004-3591","type":"print"}],"subject":[],"published":{"date-parts":[[2011,5,31]]}}}